Long ago Roche bet on personalised health care. Now its time has come.
Early attempts to tailor disease treatment to individuals based on their DNA have met with equivocal success, raising concerns about a push to scale up such efforts.
The vision would be to go beyond Precision Medicine: instead of a frantic race to cure disease after the fact, we can increasingly focus on preventing disease before it strikes. By focusing on health and wellness, we can also have a meaningful impact in reducing healthcare costs. At Stanford, we call this idea Precision Health, where we focus on helping individuals thrive based on all the factors that are unique to their lives, from their genetics to their environment.
We suggest looking to the NFL. Of course, there are major differences between the National Football League and precision medicine--no analogy is ever perfect. But if the precision medicine community could take some cues from this enterprise and create a culture of individual and joint value, it could lead to cheaper and more rapid discoveries, testing and commercialization of new therapies that can save patient lives.
A panel of experts discuss the potential—and the potential pitfalls—of the medical model that proposes personalized, targeted health care.
As with any major change in the practice of medicine, precision medicine will have to build slowly towards relevance in the field of cardiology. But the astounding promise of recent gains in other therapeutic areas underscores the potential associated with identifying subgroups of patients who can benefit from a targeted treatment. In cardiovascular disease, precision medicine may result in much-needed innovation in the field and has the potential to eventually change the way we treat heart diseases altogether.
There are few diagnoses more terrifying to patients than cancer. And accordingly, there are few visions of future healthcare that are more comforting than those promised by “precision medicine,” the idea that medical treatment will be wondrously personalized and efficient, and possibly spare us—through genomics, genetic testing, and studying personal data—from cancers and other dreaded disease. Will we ever get there?
The goal of precision medicine is to give the diabetes patient — and many others — the same sort of molecular diagnosis and targeted treatment as today’s breast cancer patient.
Precision medicine won’t work without precision questions.
Among the many stents, surgical clamps, pumps and other medical devices that have recently come before the Food and Drug Administration for clearance, none has excited the widespread hopes of physicians and researchers like a machine called the Illumina MiSeqDx. The device could accelerate the use of genetic information in everyday medical care, physicians hope, improving diagnoses and treatments.
Precision medicine promises a paradigm shift in care delivery, one that removes the need for guesswork, variable diagnoses and treatment strategies based on generalized demographics. Precision medicine approaches are enabled by data leveraged from direct and indirect sources to provide a more holistic view of an individual patient.
Personalized medicine, the hoped-for use of the information in our genes to inform our medical care, may end up helping people live longer, healthier lives. Or it may not—the jury is still out. But one thing is certain: As our unique genomic data enter our medical records, researchers will be tempted to use that invaluable resource. The results may be good for science but bad for patients’ privacy.
Precision medicine is an exciting area of innovation, but there's a long way to go before research meets quality clinical care.
For the first time, patients don’t have to go through a physician to learn about potential risks related to their genetic makeup. As long as 23andMe meets the FDA’s “special controls” for subsequent tests, they won’t have to get premarket clearance from regulators. Other companies will benefit from the same regulatory pathway after they receive their first approval for similar types of tests.
Personalized medicine is the future. It is where the science is going. It is where the technology is going. It is where doctors and patients will want to go. Yet unfortunately for many of us, this is not where the Obama administration wants to go.
There's a genetic testing revolution underway at your local hospital. And it's causing doctors and medical students to confront some very thorny issues.
"Personalized medicine" uses genetic information derived from tests to predict a patient's chances of coming down with diseases and offers ways of tailoring some cures.
A new study suggests that knowing their genetic risk of disease doesn’t motivate people to change their behavior.
Why exactly is personalized medicine such a challenge? The reasons might seem obvious – genes are really, really small; it’s hard to get enough people to study any particular target; cancer, the disease in which personalized therapy has been most touted, probably results from a combination of many genetic mutations and it’s hard to know just which one to blame.
Often called the next “space race” because of the immense technological advances required to make it a reality, precision medicine allows clinicians to advance beyond the relatively coarse diagnostic and therapeutic categories of the present day, towards a more targeted, fine-grained system...
Science has a history of inflated promises when it comes to disease treatment.
Raising awareness and recognition of Predictive, Preventive and Personalised Medicine throughout all Member-countries of the European Union and Associated countries...
The Sherpa speaks the language of the trail, he/she knows short cuts and dangerous paths to avoid. This blog is for those wishing to take the journey and those wishing to become Gene Sherpas.
Health Nucleus, a clinical research and discovery center, is the premier health intelligence platform integrating genomics, advanced clinical imaging and robust machine learning in a spa-like setting. Using our proprietary technology to identify actionable opportunities today, we empower you and your physician to proactively plan for a longer, healthy life.
The Journal of Laboratory and Precision Medicine (JLPM, J Lab Precis Med, Online ISSN: 2519-9005) is an open access, peer review, international online journal that publishes both solicited and unsolicited manuscripts aimed to reporting new findings in this field, so providing current, practical information on laboratory and precision medicine.
Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis).
NantHealth is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses.
npj Precision Oncology is a new open access, online-only, international, peer-reviewed journal committed to publishing cutting edge scientific research in all aspects of precision oncology from basic science to translational applications, to clinical medicine.
The Personalized Medicine Coalition is an independent, non-profit group that works to advance the understanding and adoption of personalized medicine for the ultimate benefit of patients. Our diverse members work together to educate opinion leaders and the public about the issues that will shape how personalized medicine develops and how quickly all of us can benefit from it.
PersonalizedMedicine.com is a free to use portal for professionals in the field of Personalized Medicine and Molecular Diagnostics.
Precision Medicine is a peer-reviewed, open access journal dedicated to the publication of papers to accelerate better individual diagnosis, prevention, and treatment.
The scope of the journal covers, but is not limited to, genomic, epigenomic, transcriptomic, proteomic, metabolomic medicine which are expected to unify molecular and clinical research at the point of individual precision healthcare.
PRECISION MEDICINE ALLIANCE is at the forefront of precision medicine. Our goal is to connect all stakeholders to our value-based platform and establish PRECISION MEDICINE FIRST in the clinical world for an optimal outcome for each individual patient and a sustainable performance of our healthcare systems.
The Journal of Precision Medicine is the world’s first print publication to discuss the many key global issues surrounding this rapidly evolving landscape. It does so by connecting both ends of the life science continuum – the compelling discoveries being realized in molecular research with the critical needs of the patient in the clinical setting. Providing a forum for the global Life Science community to share thought provoking and forward thinking opinion, The Journal of Precision Medicine will play an important role in advancing the progress already being made in this exciting field..
Theranostics Health, LLC (THX) is a pioneer in the next stage of molecular medicine: the blending of therapeutics and diagnostics to make personalized patient treatment a reality. The technology developed by the company represents a new paradigm in molecular medicine where the biomarker that services as the diagnostic is also the therapeutic target and the activity of actual protein drug targets in a patient’s tissue sample can be measured.
U.S. Preventive Medicine® has developed a suite of prevention, early detection and chronic condition management products and services that improve health outcomes while reducing health care costs. Every person at our company is working relentlessly to deliver the "ultimate prevention experience" to more people so we can one day give everyone more good years.